Easycalls.info
 

A consideration has found that peo...

A consideration has found that people with depressed incomes are more likely than other race to develop brain cancer, according to a May 24 2004 of the present days release from the American Academy of Neurology During a two-year period, researchers identified all of the present day cases of brain cancer diagnosed in patients between the ages of 25 and 84 that occurr in the state of Michigan. A total of 1006 cases were studied.

The overall brain cancer rate was 81 cases through 100,000 people. The rate of brain cancer in patients classified as having tow income based forward their eligibility to receive Medicaid, however, was 142 cases by means of 100,000 compared to 7.5 cases through 100,000 for all other patients. The difference was greatest among patients who were younger than age 44 For clan over age 67, there was no significant difference in incidence of brain cancer between patients with depressed incomes and the other patients.

The researchers do not know with what intent tow income is associated with higher rates of brain cancer. They speculate that beggary may accelerate the onset of cancer in the public who are biologically predisposed to cause to grow it, because low income status is associated with environmental factors, of that kind as exposure to toxins, poor nutrition and shelter, and education and health factors.



nation With Low Incomes More Likely to disentangle Brain Tumors (news release, St Paul, Minn: American Academy of Neurology May 24 2004) http://www.aan.com/press /press/index.cfm?fuseacfion=release.view&release=210 (accessed 25 May 2004)

COPYRIGHT 2004 Association of Operating place Nurses, Inc.

COPYRIGHT 2004 Gale Group



Other Articles
 -Administration of recombi...
 -Research published today ...
 -* Genentech, Inc. (South ...
 -Gilead Sciences (Foster C...
 -Genetech, Inc. (South San...
 -FDA designated Avastin (G...
 -RPS, Inc. (Plymouth Meeti...
 -The Analytica Group (Thor...
 -Teijin Limited (Osaka, Ja...
 -RPS, Inc. (Plymouth Meeti...
 -Ethypharm (Paris, France)...
 -For the first time time J...
 -Many of the new medicatio...
 -Mary Crowley Medical Rese...
 -Phase 3 Patients wi...
 -Sonus Pharmaceuticals, In...
 -A partnership between Pro...
 -Indeed, times are changin...
 -Results from a Phase 2 st...
 -Clinical trials conducted...
 -Clinical Project Manageme...
 -As research subjects, chi...
 -The timetable for Europea...
 -2003 Advanstar Events ...
 -Results of the Pharmacycl...
 -The FDA has approved Zema...
 -Phase 2 Most recent...
 -Identifying diverse group...
 -Recruiting children to pa...
 -A regulatory and clinical...
 -OriginLab Corporation (No...
 -Six public research insti...
 -A summary of results from...
 -Prior to adjourning for i...
 -Pharmaceutical Profiles' ...
 -Invivodata inc. (Pittsbur...
 -MAP80 Systems (Berkshire,...
 -Onyvax Ltd (London, UK) r...
 -Executives at top pharmac...
 -PhOSCo (Pharma Open Sourc...
 -Dendreon Corporation (Sea...
 -InnaPhase Corporation (Ph...
 -InfoPro Solutions (Westla...
 -* Kees Been was appointed...
 -* Albert E. Boylon joined...
 -Applied Clinical Trials i...
 -Ranbaxy Pharmaceuticals I...
 -Results from a Phase 2 cl...
 -At the beginning of the y...
 -Hollis-Eden Pharmaceutica...
 -Melissa Warner has been n...
 -Unigene Laboratories, Inc...
 -The addition of irinoteca...
 -The national Award for Ex...
 -PharmaPros Corporation (B...
 -Organon (Rosewood, NJ) an...
 -Interim results of a Phas...
 -Most pharmaceutical execu...
 -CSM of Fargo, ND, an inno...
 -Hemispherx Biopharma, Inc...
 -CenterWatch (Boston, MA) ...
 -Although this issue of Ap...
 -The editorial in the June...
 -The objective of igeneon'...
 -Advanced prostate cancer ...
 -Constella Biomedical Info...
 -CenterWatch is a Boston-b...
 -Jean Vlallet, MD, has joi...
 -The European Agency for t...
 -The Association for Clini...
 -Responding to enormous pr...
 -Many observers of the com...
 -BioSante Pharmaceuticals,...
 -Medifacts International (...
 -Kendle International Inc....
 -Duke Comprehensive Cancer...
 -FDA approved Acular LS (k...
 -A Phase 3 study involving...
 -Averion, Inc. (Framingham...
 -The European Union knows ...
 -Results of a study of Pum...
 -Inveresk (NASDAQ: IRGI) i...
 -Kos Pharmaceuticals, Inc....
 -For a comprehensive calen...
 -The Eastman Dental Instit...
 -Genentech, Inc. (South Sa...
 -Pierre Etienne, MD, is no...
 -Can subjects read, unders...
 -The Association for the A...
 -The Italian mathematician...
 -Positive Phase 2 results ...
 -Personal Service and Affo...
 -According to the latest T...
 -The Office for Human Rese...
 -Cell Therapeutics, Inc. (...
 -* Marvin Samson, presiden...
 -* Patrick T. Mooney, MD, ...
 -Day One | Monday, August ...
 -* Stanley C. Penzotti, Jr...
 -European Union health min...
 -A Phase 2 trial of 33 sub...
.
© 2006 Easycalls.info All rights reserved.